What is Nanoviricides's earnings per share (EPS)?

Nanoviricides (NNVC) reported diluted earnings per share of -$0.63 for fiscal year 2025. This represents a 10.0% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Nanoviricides Financials

NNVC

FY2025 annual

Revenue $0 YoY not available

Net Income -$9.5M -14.1% YoY

EPS (Diluted) -$0.63 +10.0% YoY

Free Cash Flow -$8.5M -31.9% YoY

Source SEC Filings (10-K/10-Q) Latest period Q3 FY2026, ended Mar 31, 2026 Reported May 15, 2026 Currency USD FYE June

Nanoviricides (NNVC) reported $0 in revenue for fiscal year 2025. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI NNVC FY2025 2026-08-29

External financing is absorbing a persistent operating cash requirement while the balance-sheet liquidity cushion narrows.

In FY2025, operating cash flow of -$8.5M nearly matched the net loss of $9.5M, so accounting losses translated into cash needs rather than being mainly non-cash. Free cash flow was -$8.5M despite only $57K of capital expenditures, locating the pressure in ongoing operations rather than expansionary reinvestment.

Financing cash flow supplied $5.3M in FY2025 as shares outstanding reached 17.4M. That funding pattern coincided with an 18.8% share-count increase from FY2024, indicating external financing is carrying the operating model with dilution.

Total assets fell from $12.8M in FY2024 to $8.8M in FY2025, shrinking the balance-sheet base while liabilities did not fall comparably. The current ratio was 1.3M and reported liquidity measured 2.2 months of annual operating outflow, pointing to a narrower short-term cushion.

Financial Health Signals

Financial health score not available

Nanoviricides does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Altman Z-Score Distress

-12.54

Nanoviricides scores -12.54, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($31.7M) relative to total liabilities ($1.3M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

1/7

Nanoviricides passes 1 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), neither operating efficiency signal passes.

Earnings Quality No Cash Backing

N/A

Nanoviricides reported a net loss of $9.5M while operations used $8.5M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Interest Coverage At Risk

N/A

Nanoviricides reported an operating loss of $9.6M against $149 in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

Nanoviricides generated $0 in revenue in fiscal year 2025.

EBITDA

-$8.8M

YoY-14.1%

Nanoviricides's EBITDA was -$8.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 14.1% from the prior year.

Net Income

-$9.5M

YoY-14.1%

Nanoviricides reported -$9.5M in net income in fiscal year 2025. This represents a decrease of 14.1% from the prior year.

EPS (Diluted)

-$0.63

YoY+10.0%

Nanoviricides earned -$0.63 per diluted share (EPS) in fiscal year 2025. This represents an increase of 10.0% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$8.5M

YoY-31.9%

Nanoviricides recorded an outflow of $8.5M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. This represents a decrease of 31.9% from the prior year.

Cash & Debt

$1.6M

YoY-67.5%

5Y CAGR-35.3%

10Y CAGR-26.0%

Nanoviricides held $1.6M in cash as of fiscal year 2025; long-term debt is not reported for that period.

Shares Outstanding

17M

YoY+18.8%

Nanoviricides had 17M shares outstanding in fiscal year 2025. This represents an increase of 18.8% from the prior year.

Dividends Per Share

Not reported for fiscal year 2025.

Margins & Returns

Return on Equity

-125.9%

YoY-53.6pp

5Y CAGR-64.1pp

10Y CAGR-119.0pp

Nanoviricides's ROE was -125.9% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 53.6 percentage points from the prior year.

Gross Margin

Not reported for fiscal year 2025.

Operating Margin

Not reported for fiscal year 2025.

Net Margin

Not reported for fiscal year 2025.

Capital Allocation

R&D Spending

$5.5M

YoY+2.1%

5Y CAGR+3.4%

10Y CAGR+4.2%

Nanoviricides invested $5.5M in research and development in fiscal year 2025. This represents an increase of 2.1% from the prior year.

Capital Expenditures

$57K

YoY-63.6%

5Y CAGR+45.8%

10Y CAGR-38.0%

Nanoviricides invested $57K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 63.6% from the prior year.

Share Buybacks

Not reported for fiscal year 2025.

NNVC Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

NNVC quarterly income statement

Metric	TTM	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11
Revenue	N/A	$0	$0	$0	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	N/A	$5.5M+2.1%	$5.4M-14.9%	$6.4M+10.5%	$5.8M-5.4%	$6.1M+30.2%	$4.7M-20.7%	$5.9M+0.1%	$5.9M-9.9%	$6.6M+30.6%	$5.0M+37.4%	$3.7M-28.7%	$5.1M+19.5%	$4.3M+0.6%	$4.3M+2.6%	$4.2M
SG&A Expenses	N/A	$4.0M+31.3%	$3.1M+20.7%	$2.6M+9.5%	$2.3M-11.4%	$2.6M-20.3%	$3.3M+20.6%	$2.7M-19.7%	$3.4M+12.4%	$3.0M-20.8%	$3.8M+12.6%	$3.4M-3.8%	$3.5M+53.9%	$2.3M+26.5%	$1.8M-20.1%	$2.3M
Operating Income	N/A	-$9.6M-12.6%	-$8.5M+4.8%	-$8.9M-10.2%	-$8.1M+7.2%	-$8.7M-9.3%	-$8.0M+7.7%	-$8.7M+7.1%	-$9.3M+2.9%	-$9.6M-8.4%	-$8.9M-25.4%	-$7.1M+18.5%	-$8.7M-31.5%	-$6.6M-8.4%	-$6.1M+5.4%	-$6.4M
Interest Expense	N/A	$149-99.7%	$50K+5210.0%	$938-81.7%	$5K-94.0%	$85K-8.8%	$94K	$0-100.0%	$185K-76.3%	$781K-25.1%	$1.0M-60.7%	$2.6M-14.3%	$3.1M+1646.8%	$177K	$0	$0
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Net Income	N/A	-$9.5M-14.1%	-$8.3M+3.4%	-$8.6M-5.9%	-$8.1M+8.1%	-$8.8M+34.4%	-$13.4M-59.6%	-$8.4M+1.6%	-$8.6M+16.9%	-$10.3M+3.9%	-$10.7M-387.9%	-$2.2M+83.8%	-$13.6M-53.2%	-$8.9M-43.0%	-$6.2M+4.2%	-$6.5M
EPS (Diluted)	-$0.43	-$0.63+10.0%	-$0.70+5.4%	-$0.74-5.7%	-$0.70+13.6%	-$0.81	N/A	N/A	-$0.13+23.5%	-$0.17+10.5%	-$0.19	-$0.09	-$0.27-42.1%	-$0.19	N/A	N/A

Metric	Q3'26	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24
Revenue	N/A	N/A	$0	N/A	N/A	N/A	$0	N/A
R&D Expenses	$1.3M+15.0%	$1.1M+12.6%	$993K	N/A	$1.3M+10.9%	$1.2M-40.2%	$1.9M	N/A
SG&A Expenses	$744K-33.2%	$1.1M+38.7%	$804K	N/A	$967K+7.1%	$903K-26.9%	$1.2M	N/A
Operating Income	-$2.0M+9.1%	-$2.2M-24.3%	-$1.8M	N/A	-$2.2M-9.2%	-$2.1M+35.0%	-$3.2M	N/A
Interest Expense	N/A	N/A	N/A	N/A	N/A	$149	N/A	N/A
Net Income	-$2.0M+10.4%	-$2.2M-24.4%	-$1.8M	N/A	-$2.2M-9.3%	-$2.0M+35.2%	-$3.1M	N/A
EPS (Diluted)	-$0.09+18.2%	-$0.11-10.0%	-$0.10+23.1%	-$0.13+7.1%	-$0.140.0%	-$0.14+39.1%	-$0.23-21.1%	-$0.19

Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, Income Tax.

NNVC Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

NNVC quarterly balance sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11
Total Assets	$8.8M-31.2%	$12.8M-24.1%	$16.9M-28.1%	$23.5M-22.4%	$30.3M+26.5%	$23.9M+77.8%	$13.4M-27.5%	$18.5M-31.3%	$27.0M-26.3%	$36.6M-17.1%	$44.2M+0.7%	$43.9M+167.3%	$16.4M+5.0%	$15.6M+45.3%	$10.8M
Current Assets	$1.7M-66.4%	$5.0M-41.1%	$8.4M-41.4%	$14.4M-30.8%	$20.8M+48.9%	$14.0M+395.0%	$2.8M-61.4%	$7.3M-52.1%	$15.3M-37.3%	$24.4M-23.0%	$31.7M-14.3%	$37.0M+154.5%	$14.5M-0.5%	$14.6M+52.7%	$9.6M
Cash & Equivalents	$1.6M-67.5%	$4.8M-41.1%	$8.1M-42.1%	$14.1M-31.4%	$20.5M+49.7%	$13.7M+436.5%	$2.6M-63.9%	$7.1M-53.1%	$15.1M-37.5%	$24.2M-23.2%	$31.5M-14.2%	$36.7M+163.6%	$13.9M-2.5%	$14.3M+54.8%	$9.2M
Total Liabilities	$1.3M-4.3%	$1.4M-33.2%	$2.0M+392.7%	$413K+17.6%	$351K-83.7%	$2.2M-24.3%	$2.8M+222.9%	$882K-86.8%	$6.7M-50.8%	$13.6M+9.5%	$12.4M-39.5%	$20.5M+144.0%	$8.4M+371.9%	$1.8M+203.1%	$587K
Current Liabilities	$1.3M-3.8%	$1.4M+154.3%	$534K+29.4%	$413K+17.6%	$351K-83.7%	$2.2M-24.3%	$2.8M+222.9%	$882K-81.1%	$4.7M-30.8%	$6.7M+1022.3%	$601K+16.1%	$518K-56.1%	$1.2M-33.8%	$1.8M+203.1%	$587K
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$0-100.0%	$5.0M	$0	$0	N/A
Total Equity	$7.5M-34.4%	$11.5M-22.9%	$14.9M-35.6%	$23.1M-22.8%	$29.9M+37.5%	$21.8M+105.3%	$10.6M-40.0%	$17.7M-13.1%	$20.3M-11.8%	$23.0M-27.5%	$31.8M+36.0%	$23.4M+191.8%	$8.0M-42.2%	$13.9M+36.2%	$10.2M
Retained Earnings	-$148.8M-6.8%	-$139.4M-6.3%	-$131.1M-7.0%	-$122.5M-7.1%	-$114.4M-8.4%	-$105.6M-14.6%	-$92.1M-10.1%	-$83.7M-11.4%	-$75.1M-15.9%	-$64.8M-19.8%	-$54.1M-4.2%	-$51.9M-235.5%	$38.3M	N/A	N/A

Metric	Q3'26	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24
Total Assets	$10.2M-16.7%	$12.3M+46.8%	$8.4M-5.3%	$8.8M-12.0%	$10.0M-13.3%	$11.6M-1.4%	$11.7M-8.4%	$12.8M
Current Assets	$3.4M-36.2%	$5.3M+322.9%	$1.3M-25.0%	$1.7M-38.7%	$2.7M-33.0%	$4.1M+0.8%	$4.0M-18.7%	$5.0M
Cash & Equivalents	$3.2M-37.6%	$5.2M+357.5%	$1.1M-27.8%	$1.6M-38.7%	$2.5M-35.8%	$4.0M+2.4%	$3.9M-19.4%	$4.8M
Total Liabilities	$1.1M-8.3%	$1.2M0.0%	$1.2M-7.7%	$1.3M+8.4%	$1.2M-0.1%	$1.2M-26.5%	$1.6M+20.2%	$1.4M
Current Liabilities	$1.1M-10.9%	$1.2M+1.1%	$1.2M-9.5%	$1.3M+9.0%	$1.2M+1.3%	$1.2M-27.5%	$1.6M+20.2%	$1.4M
Total Equity	$9.2M-17.3%	$11.1M+54.3%	$7.2M-4.6%	$7.5M-14.9%	$8.8M-15.0%	$10.4M+2.8%	$10.1M-11.8%	$11.5M
Retained Earnings	-$154.8M-1.3%	-$152.8M-1.5%	-$150.6M-1.2%	-$148.8M-1.4%	-$146.7M-1.5%	-$144.5M-1.4%	-$142.5M-2.2%	-$139.4M

Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.

NNVC Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

NNVC quarterly cash flow statement

Metric	TTM	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11
Operating Cash Flow	-$7.3M	-$8.5M-34.3%	-$6.3M-11.4%	-$5.7M+3.8%	-$5.9M+28.3%	-$8.2M-23.2%	-$6.7M+2.0%	-$6.8M+12.5%	-$7.8M+1.5%	-$7.9M-15.6%	-$6.8M-9.9%	-$6.2M+1.9%	-$6.3M-9.2%	-$5.8M-37.5%	-$4.2M+6.4%	-$4.5M
Capital Expenditures	$95K	$57K-63.6%	$157K+3.2%	$152K-53.2%	$324K+35.8%	$239K+2664.1%	$9K-88.3%	$74K-69.5%	$242K+46.6%	$165K-65.4%	$476K-93.0%	$6.8M+29.2%	$5.2M+7956.4%	$65K+178.1%	$23K-84.7%	$153K
Free Cash Flow	-$7.4M	-$8.5M-31.9%	-$6.5M-11.2%	-$5.8M+6.3%	-$6.2M+26.5%	-$8.5M-26.6%	-$6.7M+2.9%	-$6.9M+14.2%	-$8.0M+0.6%	-$8.1M-10.4%	-$7.3M+43.7%	-$13.0M-12.2%	-$11.6M-97.3%	-$5.9M-38.2%	-$4.2M+9.0%	-$4.7M
Investing Cash Flow	-$95K	-$57K+63.6%	-$157K-3.2%	-$152K+53.2%	-$324K	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	-$1.1M-1718.8%	-$59K+69.8%	-$194K
Financing Cash Flow	$8.0M	$5.3M+69.8%	$3.1M+3391.6%	-$95K+59.6%	-$235K-101.5%	$15.3M-14.4%	$17.8M+658.6%	$2.4M	$0+100.0%	-$1.0M	N/A	N/A	N/A	$6.5M-30.2%	$9.3M+33.8%	$7.0M

Metric	Q3'26	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24
Operating Cash Flow	-$1.9M+5.8%	-$2.0M-28.6%	-$1.6M+6.3%	-$1.7M+14.5%	-$2.0M+9.1%	-$2.2M+15.6%	-$2.6M-75.2%	-$1.5M
Capital Expenditures	$0-100.0%	-$1-100.0%	$84K+726.6%	$10K	$0	$0-100.0%	$47K-52.4%	$98K
Free Cash Flow	-$1.9M+5.8%	-$2.0M-22.1%	-$1.7M+2.0%	-$1.7M+14.0%	-$2.0M+9.1%	-$2.2M+17.1%	-$2.6M-67.2%	-$1.6M
Investing Cash Flow	$0-100.0%	$1+100.0%	-$84K-726.6%	-$10K	$0	$0+100.0%	-$47K+52.4%	-$98K
Financing Cash Flow	-$7K-100.1%	$6.1M+387.8%	$1.2M+71.0%	$728K+26.5%	$576K-74.8%	$2.3M+33.5%	$1.7M-45.2%	$3.1M

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

NNVC Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples.

NNVC quarterly financial ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11
Return on Equity	-125.9%-53.6pp	-72.4%-14.6pp	-57.8%-22.6pp	-35.1%-5.6pp	-29.5%+32.3pp	-61.8%+17.7pp	-79.5%-31.0pp	-48.5%+2.2pp	-50.7%-4.2pp	-46.5%-39.6pp	-6.9%+51.3pp	-58.2%+52.6pp	-110.8%-66.0pp	-44.8%+18.9pp	-63.7%
Return on Assets	-107.3%-42.6pp	-64.7%-13.9pp	-50.8%-16.3pp	-34.5%-5.3pp	-29.1%+27.1pp	-56.2%+6.4pp	-62.6%-16.5pp	-46.2%-8.0pp	-38.2%-8.9pp	-29.3%-24.3pp	-5.0%+26.0pp	-31.0%+23.1pp	-54.1%-14.4pp	-39.7%+20.5pp	-60.2%
Current Ratio	1.28-2.4x	3.66-12.1x	15.81-19.1x	34.92-24.4x	59.30+52.8x	6.49+5.5x	0.99-7.3x	8.30+5.0x	3.28-0.3x	3.62-49.1x	52.73-18.7x	71.38+59.1x	12.33+4.1x	8.20-8.1x	16.27
Debt-to-Equity	0.17+0.1x	0.120.0x	0.14+0.1x	0.020.0x	0.01-0.1x	0.10-0.2x	0.27+0.2x	0.05-0.3x	0.33-0.3x	0.59+0.6x	0.00-0.2x	0.21+0.2x	0.000.0x	0.00-0.1x	0.06

Metric	Q3'26	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24
Return on Equity	-21.7%-1.7pp	-20.1%+4.8pp	-24.9%	N/A	-25.1%-5.6pp	-19.5%+11.4pp	-30.9%	N/A
Return on Assets	-19.5%-1.4pp	-18.1%+3.3pp	-21.4%	N/A	-22.1%-4.6pp	-17.5%+9.1pp	-26.6%	N/A
Current Ratio	3.17-1.3x	4.43+3.4x	1.06-0.2x	1.28-1.0x	2.27-1.2x	3.44+1.0x	2.48-1.2x	3.66
Debt-to-Equity	0.120.0x	0.11-0.1x	0.170.0x	0.170.0x	0.140.0x	0.120.0x	0.160.0x	0.12

Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, FCF Margin.

Similar Companies

Q32 BIO INC QTTB

$447.4M

Exicure Inc XCUR

$8.4M

SAB BIOTHERAPEUTICS INC SABS

$344.8M

Lixte Biotechnology Hldgs Inc LIXT

$125.4M

Fibrobiologics FBLG

$9.6M

Where Nanoviricides Ranks

Frequently Asked Questions

What is Nanoviricides's annual revenue?

Nanoviricides (NNVC) reported $0 in total revenue for fiscal year 2025. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

Is Nanoviricides profitable?

No, Nanoviricides (NNVC) reported a net income of -$9.5M in fiscal year 2025.

What is Nanoviricides's EBITDA?

Nanoviricides (NNVC) had EBITDA of -$8.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Nanoviricides's return on equity (ROE)?

Nanoviricides (NNVC) has a return on equity of -125.9% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Nanoviricides's free cash flow?

Nanoviricides (NNVC) recorded an outflow of $8.5M in free cash flow during fiscal year 2025. This represents a -31.9% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Nanoviricides's operating cash flow?

Nanoviricides (NNVC) recorded an outflow of $8.5M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are Nanoviricides's total assets?

Nanoviricides (NNVC) had $8.8M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Nanoviricides's capital expenditures?

Nanoviricides (NNVC) invested $57K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Nanoviricides spend on research and development?

Nanoviricides (NNVC) invested $5.5M in research and development during fiscal year 2025.

How many shares does Nanoviricides have outstanding?

Nanoviricides (NNVC) had 17M shares outstanding as of fiscal year 2025.

What is Nanoviricides's current ratio?

Nanoviricides (NNVC) had a current ratio of 1.28 as of fiscal year 2025, which is considered adequate.

What is Nanoviricides's debt-to-equity ratio?

Nanoviricides (NNVC) had a debt-to-equity ratio of 0.17 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Nanoviricides's return on assets (ROA)?

Nanoviricides (NNVC) had a return on assets of -107.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

How does Nanoviricides's liquidity compare with its operating cash outflow?

At the end of fiscal year 2025, Nanoviricides (NNVC) held $1.6M in cash, cash equivalents and investments, and reported an operating cash outflow of $8.5M over that year. Dividing the one by the other, the reported balance equals about 2 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

What is Nanoviricides's Altman Z-Score?

Nanoviricides (NNVC) has an Altman Z-Score of -12.54, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Nanoviricides's Piotroski F-Score?

Nanoviricides (NNVC) has a Piotroski F-Score of 1 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Nanoviricides's earnings high quality?

Nanoviricides (NNVC) reported a net loss of $9.5M while operations used $8.5M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Nanoviricides cover its interest payments?

Nanoviricides (NNVC) reported an operating loss of $9.6M against $149 in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.